GSK R&D to Revenue
GSK plc American Depositary Shares (Each representing two Ordinary Shares) · R&D to Revenue
GSK R&D to Revenue
Latest reported20.47%period ending
GSK Quarterly R&D/Revenue (0.00% → 20.47%)
Latest values, visible window
High-resolution chart · PNG
GSK r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 20.4662% | |
| 22.1785% | |
| 27.1525% | |
| 19.7613% | |
| 24.7308% | |
| 18.587% | |
| 22.6192% | |
| 17.9855% | |
| 18.1126% | |
| 18.6473% | |
| 15.9712% | |
| 17.5279% | |
| 18.3199% | |
| 17.8392% | |
| 24.1052% | |
| 16.5666% | |
| 17.8236% | |
| 15.452% | |
| 19.4036% | |
| 21.1861% | |
| 19.493% | |
| 15.0445% | |
| 15.5624% | |
| 13.0234% | |
| 17.0908% | |
| 12.1342% | |
| 13.4847% | |
| 12.7224% | |
| 13.6893% | |
| 12.9356% | |
| 13.1268% | |
| 12.2096% | |
| 12.6539% | |
| 12.5173% | |
| 15.8267% | |
| 13.3495% | |
| 17.2131% | |
| 13.0011% | |
| 13.0899% | |
| 12.079% | |
| 13.5946% | |
| 13.084% | |
| 16.7674% | |
| 13.4976% | |
| 13.7908% | |
| 15.4216% | |
| 15.8261% | |
| 14.2225% | |
| 14.5477% | |
| 15.3038% | |
| 15.4938% | |
| 13.8249% | |
| 15.8507% | |
| 13.97% | |
| 16.7745% | |
| 14.3098% | |
| 14.268% | |
| 14.6235% | |
| 15.6922% | |
| 13.8514% | |
| 15.1042% | |
| 13.8952% | |
| 15.2425% | |
| 14.7365% | |
| 17.0249% | |
| 15.7673% | |
| 13.9239% | |
| 13.0512% | |
| 14.4212% | |
| 16.6051% | |
| 17.5398% | |
| 14.7739% | |
| 13.9598% | |
| 13.7179% | |
| 15.9474% | |
| 14.0434% | |
| 13.9055% | |
| 12.9828% | |
| 16.4493% | |
| 15.4378% | |
| 14.6807% | |
| 12.9537% | |
| 16.3898% | |
| 14.6774% | |
| 13.3845% | |
| 13.1652% | |
| 14.05% | |
| 14.1304% | |
| 14.0012% | |
| 13.5736% | |
| 15.2912% | |
| 12.4588% | |
| 12.1722% | |
| 12.1364% | |
| 15.9668% | |
| 14.0665% | |
| 11.5051% | |
| 13.0333% | |
| 11.5333% | |
| 13.1558% |